Browse the evidence

Achieving diabetes remission in type 2 diabetes patients reduces the risk of cardiovascular disease by approximately 30% compared to non-remission, independent of significant weight loss.

For patients with type 2 diabetes, achieving remission (normal blood glucose without medication) is a critical goal for preventing heart disease. This benefit exists even if you do not lose significant weight, suggesting that metabolic improvements (like reduced liver/pancreas fat) are key. Focus on achieving remission through available treatments rather than solely on weight loss metrics.

Continuous Glucose Monitoring (CGM) reveals that postprandial hypoglycemia is significantly more prevalent (up to 75%) than previously thought, with a large proportion of episodes being asymptomatic.

Standard blood tests might miss hypoglycemia after gastric bypass. If you are at risk, ask your doctor about Continuous Glucose Monitoring (CGM) to detect silent low blood sugar episodes that could affect your brain health.

In overweight or obese adults with type 2 diabetes, intensive lifestyle intervention (ILI) eliminates the association between weight variability and increased risk of major adverse cardiovascular events (MACE), whereas without ILI, high weight variability significantly increases MACE risk.

If you have type 2 diabetes and are overweight, do not avoid weight loss because you are afraid of weight fluctuations. Engage in a structured, intensive lifestyle program (diet and exercise counseling). This paper shows that the weight changes resulting from such a program do not increase your risk of heart events, unlike unmanaged weight variability.

Higher Body Mass Index (BMI) causally reduces subjective wellbeing, specifically by lowering satisfaction with health.

If you are carrying excess weight, it is likely affecting your mental wellbeing, specifically your satisfaction with your health. This is not just 'in your head' but a causal effect. Addressing your BMI through lifestyle changes may improve your subjective wellbeing and health satisfaction.

High HDD diets shift gut microbial community composition from fiber-degrading taxa (e.g., Prevotella) to mucin-degrading taxa (e.g., Bacteroides, Akkermansia) due to nutrient limitation.

If you eat a diet low in fiber and high in processed ingredients, your gut bacteria may shift to eat your gut lining (mucin) instead of your food. To encourage beneficial fiber-eating bacteria, increase your intake of whole plant foods.

Replacing saturated fatty acids (SFA) with polyunsaturated fatty acids (PUFA) reduces coronary heart disease (CHD) risk by 2-3% for every 1% of energy substituted, whereas replacing SFA with low-quality carbohydrates (refined starches/sugars) provides no such benefit and may increase risk.

If you want to lower your heart disease risk by reducing saturated fats (like those in animal fats), you must replace them with unsaturated fats (like those in fish, nuts, or olive oil). Do not replace them with refined carbohydrates like white bread, pasta, or sugar, as this offers no cardiovascular benefit and may increase risk. Focus on the quality of the replacement, not just the reduction of fat.

Supplementation with marine long-chain n-3 polyunsaturated fatty acids (EPA and DHA) reduces cardiovascular risk in primary prevention and secondary prevention for patients with low baseline status and limited polypharmacy, but recent trials show null results in highly medicated secondary prevention populations.

Aim to eat fatty fish regularly to get EPA and DHA. If you are not eating fish, consider supplementation, especially if you have low baseline levels. However, if you are already on many heart medications, the added benefit of supplements may be minimal.

High carbohydrate intake is associated with increased all-cause mortality, whereas high fat intake (including saturated fat) is associated with lower all-cause mortality and lower stroke risk.

Consider reducing high carbohydrate intake, as it is associated with higher all-cause mortality. Moderate saturated fat intake may be beneficial for stroke prevention, but the overall impact on cardiovascular mortality is unclear.

Low-carbohydrate diets (ketogenic diets) lead to greater short-term weight loss and improved triglyceride levels compared to low-fat diets, but may have less favorable effects on LDL cholesterol.

For short-term weight loss and improved triglyceride levels, a low-carbohydrate diet may be more effective than a low-fat diet. However, monitor LDL cholesterol levels, as they may not improve or may worsen.

When resistance training is performed to volitional fatigue, muscle hypertrophy is independent of the external load used (high vs. low), provided volume load is matched or effort is equivalent.

You do not need to lift heavy weights to build muscle. If you use lighter weights (30-40% of your max), you must perform more reps (20-25) and push until you physically cannot complete another rep with good form. This effort-to-failure approach yields the same muscle growth as heavy lifting (70-80% max) done for fewer reps (8-12). Ensure you eat enough protein (at least 1.6g per kg of body weight) and train consistently 3 times a week.

Social support from family and friends is a significant factor in maternal exercise adherence, but often acts as a barrier due to negative or uninformed advice.

Your family's advice might be wrong. Many people discourage pregnant women from exercising due to outdated beliefs. If you are active, proactively share reliable information with your family to turn their potential discouragement into support.

A 16-week behavioral weight loss intervention produces equivalent clinically significant weight loss in high-obesity-prevalence regions (Alabama) and low-obesity-prevalence regions (Colorado), indicating that regional environmental factors are not primary barriers to individual weight loss success.

If you are struggling with weight loss in a region known for high obesity rates, do not assume your location makes success impossible. This study demonstrates that a structured 16-week behavioral program can yield significant weight loss (approx. 11%) regardless of whether you live in a high-obesity area like Alabama or a low-obesity area like Colorado. Focus on adherence to the program rather than blaming your environment.

Participants in high-obesity-prevalence regions (Alabama) demonstrate greater improvements in objective physical activity metrics (steps, stepping time, activity score) and favorable psychosocial factors (hedonic eating, social support) compared to those in low-obesity-prevalence regions (Colorado) during a behavioral weight loss intervention.

While weight loss amounts may be similar across regions, the behavioral journey differs. People in high-obesity regions may benefit from leveraging social support and managing hedonic eating triggers, as this study showed greater improvements in these areas for participants in Alabama. Building a strong support network is a key lever for success.

Using lean body mass (LBM) and body fat percentage (BF) in reference equations for peak oxygen uptake (VO2peak) provides better calibration for overweight and obese individuals compared to equations based on total body mass.

If you are overweight or obese, standard fitness tests that use your total body weight to predict your maximum oxygen uptake (VO2peak) likely overestimate your fitness level. To get an accurate assessment of your cardiorespiratory health, especially if you are older, use reference equations that account for your lean body mass and body fat percentage. This prevents being falsely categorized as 'fit' when your actual functional capacity may be lower.

Long-term caloric restriction (25% reduction for 24 months) induces metabolic adaptation (adaptive thermogenesis) in sleeping energy expenditure that exceeds predictions based on changes in body mass alone, with the effect persisting at 24 months when assessed using advanced MRI-derived organ and tissue mass models.

If you restrict calories by 25% for two years, your body will adapt by lowering its energy expenditure more than expected from weight loss alone. This 'metabolic adaptation' is real and persists, especially when looking at organ-level changes. To manage this, focus on preserving muscle mass through resistance training and protein intake, as the study shows lean tissue loss is part of the equation, though not the whole story of metabolic slowdown.

Habitual endurance or resistance exercise training enhances insulin-stimulated glycogen synthesis in primary human skeletal muscle stem cells compared to sedentary controls, but does not confer intrinsic protection against fatty acid-induced insulin resistance.

If you are highly active, your skeletal muscle cells are better at storing glucose as glycogen when insulin is present, regardless of whether you primarily do cardio or weight training. However, this cellular adaptation does not appear to protect your muscle cells from the negative effects of high fat exposure in a lab setting. To maximize metabolic health, maintain high activity levels, but be aware that cellular adaptations to training may not fully shield you from all metabolic insults like high lipid loads.

Hypercaloric 16:8 time-restricted eating (TRE) allows well-trained individuals to achieve similar gains in fat-free mass and strength as continuous feeding (FED) during resistance training, despite a reduction in total training volume.

If you are already training regularly and want to build muscle, you can compress your eating into an 8-hour window without losing gains, as long as you eat enough total calories (a slight surplus) and hit your protein targets (around 2.2g/kg). You might train slightly less volume, but your strength and muscle mass will still increase similarly to eating throughout the day. Focus on consistency and total intake, not just when you eat.

While fat-free mass gains are similar, 16:8 TRE results in less fat mass accumulation and lower total training volume compared to continuous feeding during a caloric surplus.

Be aware that if you switch to an 8-hour eating window, you might naturally train for less total volume and accumulate slightly less fat than if you ate all day, even in a surplus. This isn't necessarily bad—it might mean you are more efficient with your energy—but it is a trade-off to consider if your goal is maximum fat gain (bulking).

Treatment with maximal-tolerated dose tirzepatide (10-15 mg weekly) for 72 weeks produces substantial weight loss and health risk reduction, but typically fails to return average Class II obese individuals to the healthy BMI (<25 kg/m2) or healthy Body Roundness Index (BRI) ranges.

If you are taking tirzepatide at a high dose, expect significant health improvements and weight loss, but do not expect to automatically reach a 'healthy' BMI of under 25. The average patient in the major trials remains in the overweight or obese category even after a year. Focus on the reduction in health risks (like visceral fat/BRI) rather than just hitting a specific BMI number.

Semaglutide 2.4 mg weekly significantly improves symptoms, functional capacity, and reduces systemic inflammation in obese patients with heart failure with preserved ejection fraction (HFpEF).

If you have heart failure with preserved ejection fraction and are obese, ask your doctor about semaglutide. It is a once-weekly injection that has been shown to significantly improve your heart failure symptoms, exercise capacity, and reduce inflammation. While it may cause temporary stomach issues, the benefits for your heart and weight are substantial.

Genetic variation in the NBEA gene predicts weight loss response to GLP-1 receptor agonists (GLP-1RAs), with specific NBEA scores identifying individuals likely to be highly responsive or non-responsive to treatment.

If you are prescribed a GLP-1RA like semaglutide or liraglutide, ask your doctor about genetic testing for the NBEA gene. This test can predict whether you are likely to lose significant weight (top 20% responders) or not respond at all. This helps avoid wasting time and money on medications that are unlikely to work for your specific biology, allowing for a more personalized and effective obesity treatment plan.

Achieving ≥20–25% early postoperative weight loss (EWL) within the first 3–6 months after bariatric surgery strongly predicts sustained long-term weight loss (≥50% EWL) and metabolic remission.

If you had bariatric surgery, your weight loss in the first 3-6 months is a major predictor of your long-term success. Aim for at least 20-25% excess weight loss in this window. If you are slower, do not give up; this is a signal for your medical team to intensify support (nutrition, behavioral therapy, or medication) to help you catch up.

Semaglutide 2.4 mg is recommended for secondary prevention of cardiovascular events in individuals with BMI ≥27 kg/m² without diabetes but with established cardiovascular disease.

If you have established heart disease, are overweight (BMI ≥27), and do not have diabetes, ask your doctor about semaglutide 2.4 mg. This medication is recommended to help prevent future heart attacks, strokes, and cardiovascular death.

Bariatric surgery (VSG and RYGB) improves metabolic health and promotes weight loss by altering gut microbiota to increase the production of specific metabolites (licoricidin and butyrate) that activate thermogenesis in adipose tissue.

Bariatric surgery's success is largely due to how it changes your gut bacteria to burn more fat, not just by making you eat less. This suggests that targeting gut health and metabolism could be key to treating obesity, potentially leading to new non-surgical treatments.